{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.422","value":"79.35"},{"groupId":"OG001","spread":"16.536","value":"82.94"}]}],"title":"Expectations of Therapy (n=280,141)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.594","value":"60.69"},{"groupId":"OG001","spread":"23.339","value":"57.62"}]}],"title":"Feelings about Side Effects (n=276,141)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.428","value":"85.92"},{"groupId":"OG001","spread":"13.451","value":"83.60"}]}],"title":"Satisfaction with Therapy (n=278,141)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For Cycle 1, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion; subsequent doses were given as 1400 mg via SC injection. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG000","title":"Rituximab SC"},{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For all cycles, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG001","title":"Rituximab IV"}],"paramType":"MEAN","populationDescription":"ITT Population (CTSQ Subpopulation): All participants who completed the CTSQ at Cycles 3 and 7; number (n) = number of participants in the analysis for the specified domain.","reportingStatus":"POSTED","timeFrame":"At Cycle 7 (each cycle was 14 or 21 days)","title":"Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}